Seamless Therapeutics, a Dresden, Germany-based biotechnology company providing a recombinase platform, raised $12.5M in Seed funding.
The round was led by Wellington Partners and Forbion, with non-dilutive funding from BMBF GO-Bio. Representatives from both Wellington and Forbion will join the company’s newly formed board of directors.
The company intends to use the funds to further advance its proprietary technology platform to build a pipeline of therapeutic candidates towards first-in-human readiness as well as to expand the presence in the EU & US.
Led by CEO Anne-K. Heninger, and CSO Felix Lansing, Seamless Therapeutics is applying its proprietary know-how to develop a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing. The platform has succeeded in reprogramming site specific recombinases to any given target sequence and make a range of specific changes including inversion, excision, exchange, and insertion from small to larger DNA fragments. Recombinases are a class of enzymes that have been widely used in scientific research for decades to precisely modify the genome of model organisms but until now could not be applied as a therapeutic due to their limited programmability to act on new target sites.
FinSMEs
16/03/2023